Best Sellers
Retatrutide (Pen)
Price range: £49.99 through £113.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks
Retatrutide (Vial)
Price range: £58.99 through £92.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks
SLU-PP-332
£79.99SLU-PP-332
Metabolic — Exercise Mimetic / ERR Agonist
Synthetic ERRα/β/γ pan-agonist · small molecule
SLU-PP-332 is a first-in-class synthetic pan-agonist of the oestrogen-related receptor (ERR) family — ERRα, ERRβ, and ERRγ. Developed at Saint Louis University, it activates the same nuclear receptor transcription factors as aerobic exercise, producing measurable improvements in endurance, fat oxidation, and metabolic health in preclinical models without physical activity. It represents one of the most promising “exercise mimetic” compounds in current research.
Class
ERRα/β/γ pan-agonist — small molecule
Developer
Saint Louis University (Bhatt lab)
Stage
Preclinical — 2023/24 landmark studies
Tesamorelin
Price range: £22.99 through £90.99Tesamorelin
Hormonal — GHRH Analogue Tesamorelin
An FDA-approved synthetic GHRH analogue (Egrifta®) for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
It is unique among GH-axis peptides in having genuine regulatory approval, and its clinical data provides high-quality evidence for its mechanism and effects on body composition.
- Approval: FDA 2010 (Egrifta®)
- Indication: HIV lipodystrophy — visceral fat
- Half-Life: ~26 minutes
Tirzepatide (Pen)
Price range: £54.99 through £74.99Tirzepatide
Metabolics & GLP-1 — GIP + GLP-1 Dual Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Clinical trials demonstrate superior weight loss compared to semaglutide, with up to 22.5% mean body weight reduction at 15 mg weekly dosing.
Tirzepatide (Vial)
Price range: £34.99 through £54.99Tirzepatide
Metabolics & GLP-1 — GIP + GLP-1 Dual Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Clinical trials demonstrate superior weight loss compared to semaglutide, with up to 22.5% mean body weight reduction at 15 mg weekly dosing.
